TrialJournal of clinical pharmacology2017

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.

Susan E Shoaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.